Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

12 Apr 2005

• By John Rancourt

Related Content

Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit

17 Dec 2004

Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says

11 Aug 2004

Iressa Survival Data Adequately Disseminated To Physicians/Patients, Cmte. Says

04 Mar 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.